Market Place
Sourcing Support
After an uphill struggle, Eliem fittingly becomes Climb Bio
03 Oct 2024 //
FIERCE PHARMA
Eliem Rebrands to Climb Bio, Inc.
02 Oct 2024 //
GLOBENEWSWIRE
Eliem Therapeutics To Join Stifel Virtual Immunology And Inflammation Summit
11 Sep 2024 //
GLOBENEWSWIRE
Eliem Therapeutics Announces Additions to its Leadership Team
26 Aug 2024 //
GLOBENEWSWIRE
Eliem Therapeutics Reports Second Quarter Financial Results
14 Aug 2024 //
GLOBENEWSWIRE
Eliem Therapeutics Added To Russell 2000® And Russell 3000® Indexes
28 Jun 2024 //
GLOBENEWSWIRE
Eliem Announces the Closing of its Acquisition of Tenet Medicines
27 Jun 2024 //
GLOBENEWSWIRE
Eliem To Acquire Tenet, $120M Private Placement
11 Apr 2024 //
GLOBENEWSWIRE
Eliem cuts in on Tango, proposing acquisition after review
19 Mar 2024 //
FIERCE BIOTECH
Eliem Therapeutics Announces Plans to Explore Strategic Alternatives
20 Jul 2023 //
GLOBENEWSWIRE
Eliem shuts down final drug program 5 months after major layoffs
20 Jul 2023 //
FIERCE BIOTECH
Eliem Therapeutics Reports First Quarter Financial Results & Business Highlights
11 May 2023 //
GLOBENEWSWIRE
Eliem Therapeutics Reports Fourth Quarter and Year-End Financial Results
06 Mar 2023 //
GLOBENEWSWIRE
Eliem axes depression drug, lays off 55% of team to stretch cash
11 Feb 2023 //
FIERCE BIOTECH
Eliem Therapeutics Provides Strategic Update and Announces Leadership Transition
09 Feb 2023 //
GLOBENEWSWIRE
Eliem Therapeutics at the 5th Annual Evercore ISI HealthCONx Virtual Conference
30 Nov 2022 //
GLOBENEWSWIRE
Eliem Therapeutics Reports Third Quarter Financial and Business Highlights
14 Nov 2022 //
GLOBENEWSWIRE
Eliem Therapeutics to Participate at Two Upcoming Investor Conferences
08 Nov 2022 //
GLOBENEWSWIRE
Battered by Setbacks, Eliem is Back on Track in MDD
06 Oct 2022 //
BIOSPACE
FDA rejects Eiger`s emergency use request for repurposed Covid-19 treatment
06 Oct 2022 //
ENDPTS
Eliem Therapeutics Provides Update on Pipeline Progress
05 Oct 2022 //
GLOBENEWSWIRE
Eliem- Drug exposure issues have been resolved, drops one epilepsy indication
05 Oct 2022 //
ENDPTS
Eliem Therapeutics Reports Second Quarter Financial and Business Highlights
15 Aug 2022 //
GLOBENEWSWIRE
Eliem’s pain drug fails second PhII trial, gets scrapped
03 Aug 2022 //
ENDPTS
Eliem Therapeutics Provides ETX-810 Program Update
02 Aug 2022 //
GLOBENEWSWIRE
Eliem Announces Updated Development Plans and the Advancement of ETX-155 for MDD
18 Jul 2022 //
GLOBENEWSWIRE
Eliem Therapeutics to Host Virtual Investor Event on July 21, 2022
07 Jul 2022 //
GLOBENEWSWIRE
Eliem Tx`s Last Patient Completed Dosing in PIIa Study of ETX-810 in LSRP
27 Jun 2022 //
GLOBENEWSWIRE
Eliem Therapeutics Reports First Quarter Financial and Business Highlights
16 May 2022 //
GLOBENEWSWIRE
Results are unambiguous`: Eliem`s lead program fails and share price halves
25 Apr 2022 //
ENDPTS
Eliem Provides Update on ETX-810 and ETX-155 Clinical Programs
25 Apr 2022 //
GLOBENEWSWIRE
Eliem Therapeutics Appoints Susan Franks as SVP and Head of Regulatory Affairs
05 Apr 2022 //
GLOBENEWSWIRE
Eliem Therapeutics to Present at Stifel`s 2022 CNS Days
21 Mar 2022 //
GLOBENEWSWIRE
Eliem Tx Reports Q4 and Year-End Financial
07 Mar 2022 //
GLOBENEWSWIRE
Eliem Tx to Present at the 11th Annual SVB Leerink Conference
11 Feb 2022 //
GLOBENEWSWIRE
Eliem Tx Host Virtual Investor Event
07 Feb 2022 //
GLOBENEWSWIRE
Eliem Therapeutics Provides Program Updates
18 Jan 2022 //
GLOBENEWSWIRE
Eliem Therapeutics Reports Second Quarter Financial Results
13 Sep 2021 //
GLOBENEWSWIRE
Eliem Therapeutics Announces Closing of Initial Public Offering
13 Aug 2021 //
GLOBENEWS WIRE
3-peat Friday: Castle Creek, Eliem and Adagio file for IPOs
19 Jul 2021 //
FIERCEBIOTECH
Eliem Therapeutics Announces $60 Million Series B Financing
24 May 2021 //
PRESS RELEASE
